A PHASE I/II, OPEN LABEL STUDY OF SPC2996 IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED FOLLICULAR OR LYMPHOPLASMACYTIC NON-HODGKIN’S LYMPHOMA Primary: 1. To determine the MTD of SPC2996 in combination with rituximab in patients with relapsed follicular or lymphoplasmacytic non-Hodgkin’s lymphoma 2. To determine the overall response rate (Co...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered to Treatment-Naïve Subjects with Chronic Hepatitis C (CHC) Infection The primary objective of this study is to determine the safety and tolerability of multiple doses of miravirsen in HCV genotype 1 infected subjects

• Pays Aucun
• Organes Aucun
• Spécialités Aucune